The safety of metronidazole in pregnancy
Bibliographic Data
| ID | 15218681 |
|---|---|
| Authors | Ozioma C Nwosu (University of North Florida, corresponding author), Kathaleen C Bloom (0000-0002-8139-0914, University of North Florida), Kathaleen Bloom (University of North Florida) |
| Year | 2021 |
| Volume | 42 |
| Issue | 4-6 |
| Pages | 726-738 |
| Publication date | 2021-03-19 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Health Care For Women International (JOURNAL) |
| Journal identifiers | ISSN: 0739-9332 • E-ISSN: 1096-4665 |
| Publisher | Taylor & Francis (PUBLISHER • GB) |
| DOI | 10.1080/07399332.2021.1882462 |
| PMID | 33739240 |
| OpenAlex | W3139328480 |
| Language | EN |
| References cited | 11 |
Medication use during pregnancy carries risks of teratogenicity, preterm birth, and spontaneous abortion. CDC's guidelines advocate for the use of metronidazole for the treatment of bacterial vaginosis (BV) in pregnant women. A literature review assessing the safety of metronidazole during pregnancy was conducted. Metronidazole was found to be effective in preventing preterm births when used in conjunction with other antibiotics. Its use did not predict birth defects or congenital abnormalities. It was however associated with a 70% increased risk of spontaneous abortion. This risk should be interpreted cautiously in light of the confounder which is the severity of genitourinary infection
Abortion · Antibiotics · Bacterial vaginosis · Confounding · Genitourinary system · Gynecology · Metronidazole · Obstetrics · Pregnancy · Vaginitis · Medical Malpractice and Liability Issues · Medicine · Reproductive Health and Contraception · Syphilis Diagnosis and Treatment · Internal Medicine
| Highly cited | No |
|---|